Business
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta ("Trelegy") to GSK (NYSE: GSK) for $225 million in cash.
About this update from Gsk Plc
[{"type":"list","items":[{"val":[{"type":"text","content":"Definitive agreement to result in one-time $225 million cash payment ","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"$225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billion","length":302,"tagName":"p"}]},{"val":[{"type":"text","content":"First outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning excess capital to shareholders","length":171,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":748,"olType":false},{"type":"text","content":"DUBLIN, June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta ("Trelegy") to GSK (NYSE: GSK) for $225 million in cash.","length":347,"tagName":"p"},{"type":"image","alt":"Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)","displaySize":"","headline":null,"caption":"Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":94,"url":"https://media.zenfs.com/en/prnewswire.com/4d2df003249986704ef2ebec0198a9bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TieXGW9Z.06hTRGzjaP4Fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4d2df003249986704ef2ebec0198a9bd","width":400,"height":94}},"href":"https://mma.prnewswire.com/media/557290/Theravance_Biopharma_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Through this agreement with GSK to monetize our outer-year Trelegy royalties, we are translating our long-standing confidence in Trelegy&...